Zasocitinib (TAK-279), a Highly Selective Oral TYK2 Inhibitor, Demonstrates Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis: Post Hoc Analyses of a Randomized Phase IIb Trial

By afschroeder • May 17, 2026

Elbuluk N, Armstrong AW, Vender R, Bhutani T, Green L, Ferris LK, Laquer V, Moore A, Weisman J, Zhang W, Winkelman W, Gooderham MJ. Zasocitinib (TAK-279), a Highly Selective Oral TYK2 Inhibitor, Demonstrates Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis: Post Hoc Analyses of a Randomized Phase IIb Trial. Dermatol Ther (Heidelb). 2026 May 16. doi: 10.1007/s13555-026-01738-6. Epub ahead of print. PMID: 42143206.

Tags: Dermatology, DLQI, Oral therapy, PASI, patient-reported outcomes, plaque psoriasis, psoriasis, Publications, Skin clearance, TYK2 inhibitor, Zasocitinib

Response to Barnawi et al., “Bullous pemphigoid in the era of immunotherapy: Implications for treatment algorithms”

Kasperkiewicz M, Adotama P, Tomayko MM, Culton DA. Response to Barnawi et al., "Bullous pemphigoid in the era of immunotherapy: Implications for treatment algorithms". J[...]

Multi-cytokine based TWAS for seven inflammatory skin disorders identify candidate causal genes in keratinocytes

Zhang H, Patrick MT, Sarkar MK, Bogle R, Li Q, Uppala R, Perez White BE, Petukhova L, Dand N, Stuart PE, Christiano AM, Simpson MA,[...]

Increased risk of spontaneous abortion risk with alopecia areata independent of antiphospholipid syndrome and endometritis

Podolsky AS, Singal A, Goh C, Lipner SR. Increased risk of spontaneous abortion risk with alopecia areata independent of antiphospholipid syndrome and endometritis. J Am[...]